Ge Healthcare Technologies Inc Stock Price, News & Analysis

GE HealthCare (Nasdaq: GEHC) presented University of Michigan findings at ANESTHESIOLOGY 2025 (Oct 10–14) showing End-tidal Control software was associated with lower anesthetic use and emissions in real-world care. The retrospective analysis covered 14,730 adult general anesthesia cases, with End-tidal Control used in 50.5% of cases and active for 82.1% of the maintenance phase. Preliminary results reported reductions of greater than 35% in fresh gas flow, sevoflurane utilization and CO2 emissions during maintenance. The release notes prior GE funding of the study and references additional supporting abstracts and a separate Missouri study with similar lower-flow and cost findings.

GE HealthCare (Nasdaq: GEHC) unveiled Carestation 850, a next-generation anesthesia delivery system with FDA 510(k) pending, following a recent CE mark and approvals in Australia and New Zealand. The system targets perioperative precision with an ergonomic, space-conscious design, continuously optimized algorithms, a widescreen display, refill-while-in-use vaporization and customizable applications for patients from neonates to the elderly. GE HealthCare will showcase Carestation 850 at ANESTHESIOLOGY 2025 (Oct 10–14) at booth #1314. The release cites workforce strain—an estimated 68% of anesthesia professionals at high burnout risk and a projected anesthesiologist shortage of 12,500 by 2033—as drivers for technology adoption and efficiency improvements.

GE HealthCare (Nasdaq: GEHC) has scheduled its third quarter 2025 financial results announcement for October 29, 2025, before market opening. The company's management team will host a conference call and webcast at 8:30 AM ET / 7:30 AM CT on the same day.

Investors can access the live webcast through the company's investor relations website at investor.gehealthcare.com. The earnings release, financial information, and webcast replay will also be available at the same location.

GE HealthCare (Nasdaq: GEHC) has unveiled significant updates to its Intelligent Radiation Therapy (iRT) solution at ASTRO 2025. The AI-supported software aims to revolutionize radiation therapy workflow management, with early adopters reporting reduction in simulation-to-treatment planning time from seven days to seven minutes.

The enhanced iRT features include analytics reporting, staff scheduling, AI-powered organ auto-segmentation, virtual reality patient education, and improved system connectivity. Additionally, GE HealthCare introduced a new iRT capability for theranostics to manage complex workflows in this emerging field.

The solution addresses critical inefficiencies in radiation therapy, which affects 60% of cancer patients but traditionally faces delays of up to 30 days to begin treatment. The company will showcase these innovations along with other radiation oncology solutions at ASTRO 2025 in San Francisco.

GE HealthCare (Nasdaq: GEHC) has announced its quarterly dividend payment. The company's Board of Directors has declared a cash dividend of $0.035 per share for the third quarter of 2025. The dividend will be paid on November 14, 2025, to shareholders of record as of October 24, 2025.

GE HealthCare (Nasdaq: GEHC) has announced plans to acquire icometrix, a Belgian AI-powered brain imaging analysis company, to enhance its neurological care portfolio. The acquisition centers on icometrix's icobrain platform, which includes icobrain aria - the first FDA-cleared AI solution for detecting side effects of Alzheimer's disease amyloid targeting therapies.

The strategic acquisition aims to integrate icometrix's technology with GE HealthCare's MRI systems, enhancing clinical decision support for neurological disorders. icobrain's capabilities extend to analyzing brain MRI scans for conditions including multiple sclerosis, dementia, epilepsy, stroke, and traumatic brain injury. The deal, to be funded with cash on hand, addresses the growing demand for MRI monitoring in Alzheimer's treatment, particularly as the number of adults with the disease is projected to double by 2050.

GE HealthCare (NASDAQ: GEHC) has announced a Distribution and Services Agreement with CardioNavix, part of CDL Nuclear Technologies, to distribute Flyrcado™ (flurpiridaz F18), a cardiac PET imaging agent. The collaboration aims to expand access to cardiac PET imaging across the U.S., particularly in outpatient and private practice settings.

CDL and CardioNavix currently support 220,000 cardiac PET procedures annually through nearly 225 U.S. customer sites. The initial rollout will begin in late 2025, with broader expansion throughout 2026. This partnership combines CardioNavix's comprehensive program setup and support with GE HealthCare's contract manufacturing organization network to accelerate site enablement.

GE HealthCare (Nasdaq: GEHC) has launched the Vivid™ Pioneer, its most advanced AI-powered cardiovascular ultrasound system, after receiving CE Mark and FDA 510(k) clearance. The system features next-generation cSound™ Pioneer architecture and sophisticated probe technology for enhanced cardiac imaging.

The Vivid Pioneer offers up to 360% faster AI performance and introduces intelligent tools including AI Cardiac Auto Doppler, Easy AFI for strain results in under 9 seconds, and 4D Auto LHQ. The system's ergonomic design includes a simplified interface, larger screen, customizable touch panel, and onboard battery for uninterrupted workflow.

GE HealthCare (Nasdaq: GEHC) has announced several newly CE-marked cardiology innovations ahead of the European Society of Cardiology (ESC) Congress 2025. The company's latest solutions aim to address cardiovascular disease, which causes an estimated 20.5 million deaths globally.

Key innovations include the AI-powered ViewPoint EchoPilot™ for automated echo measurements, CardIQ Suite™ for advanced cardiac image analysis, Revolution™ Vibe CT system featuring one-beat cardiac imaging, and ComboLab™ AltiX AI.i for electrophysiology and hemodynamic recording. The company will also unveil a new cardiovascular ultrasound system at ESC 2025 in Madrid.

These solutions integrate AI and automation to streamline cardiac workflows, enhance diagnostic confidence, and improve efficiency across the entire cardiac care pathway from screening to follow-up.